Notable Labs to Present Data on September 4th at SOHO 2024

Rhea-AI Summary

Notable Labs (Nasdaq: NTBL) will present data on its volasertib program for acute myeloid leukemia (AML) at the Society of Hematologic Oncology (SOHO) 2024 meeting on September 4th. The presentation will provide an overview of the upcoming Phase 2 program and additional preclinical study results.

The poster, titled 'Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemia', will be presented during the poster session on Wednesday, September 4th at 6:15 PM CDT. Notable Labs, a clinical-stage precision oncology company, is developing new cancer therapies identified by its Predictive Medicine Platform (PMP).

The company expects to begin its Phase 2 volasertib AML program in the coming months, marking a significant step in the development of this potential treatment for AML patients.

Society of Hematologic Oncology (SOHO) session to highlight volasertib program

Phase 2 volasertib AML program expected to begin in the coming months

FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), being held from September 4^th-7^th 2024.

Presentation details:
Poster:	Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemia
Authors:	G. Michelson, S. Houston, C. Leonardi, C. Gu, M. Lacher, and J. Wagner
Poster Session:	Wednesday, September 4th at 6:15 PM CDT

About Volasertib

Volasertib is a PLK-1 inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical need, including solid tumors. Building on the performance of volasertib on PMP, an important and proprietary step during Notable’s targeted in-licensing strategy and decision making, Notable will utilize its PMP to predict volasertib-responsive patients prior to their treatment, with the goal of selectively enrolling and treating those predicted responders, increasing volasertib’s response rates and overall patient outcomes, and fast-tracking volasertib’s remaining clinical development. Volasertib was originally developed and manufactured by Boehringer Ingelheim and previously granted Breakthrough Therapy Designation by the FDA. Notable in-licensed volasertib and has exclusive worldwide development and commercialization rights, except for certain rare pediatric cancers.

About Notable Labs, Ltd.

Notable Labs, Ltd. is a clinical-stage platform therapeutics company developing predictive medicines for patients with cancer. Through its proprietary Predictive Medicine Platform (PMP), Notable aims to predict whether or not a patient is likely to respond to a specific therapeutic. The PMP is designed to identify and select clinically responsive patients prior to their treatment, potentially fast-tracking clinical development. By continually advancing and expanding the reach of the PMP across diseases and predicted medical outcomes, Notable aims to be the leader in predictive medicine and revolutionize the way patients seek and receive treatments that work best for them.

Notable believes the use of PMP also provides the Company with a more targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, with a greater likelihood of success, than traditional drug development. By transforming historical standards of care, Notable aims to create a dramatically positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California.

Learn more at the Company’s website: https://notablelabs.com/ and follow us @notablelabs.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable’s future operations and goals; the potential benefits of any therapeutic candidates or platform technologies of Notable; the timing of any clinical milestones of Notable’s therapeutic candidates; the cash runway of the Company; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and are based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Notable’s control. Notable’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) uncertainties associated with Notable’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (ii) risks related to the inability of Notable to obtain sufficient additional capital to continue to advance these product candidates and any preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) risks associated with Notable’s future financial and operating results, including its ability to become profitable; (vi) Notable’s ability to retain key personnel; (vii) Notable’s ability to manage the requirements of being a public company; (viii) uncertainties relating to the Israel-Hamas war; (ix) Notable’s ability to obtain orphan drug designation, and the associated benefits, for any of its drug candidates; (x) Notable’s inability to obtain regulatory approval for any of its drug candidates; and (xi) changes in, or additions to international, federal, state or local legislative requirements, such as changes in or additions to tax laws or rates, pharmaceutical regulations, and other regulations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (“SEC”), including the factors described in the section titled “Risk Factors” in the Annual Report on Form 10-K of Notable Labs, Ltd. for the year ended December 31, 2023 as filed with the SEC, and in other subsequent filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Notable expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CONTACTS:

Investor Relations: 

Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com

FAQ

When will Notable Labs present data on volasertib at SOHO 2024?

Notable Labs (NTBL) will present data on volasertib at SOHO 2024 on September 4th, 2024, during the poster session at 6:15 PM CDT.

What is the focus of Notable Labs' presentation at SOHO 2024?

The presentation will focus on Notable Labs' volasertib program for acute myeloid leukemia (AML), including an overview of the Phase 2 program and additional preclinical study data.

When is Notable Labs (NTBL) expected to begin its Phase 2 volasertib AML program?

Notable Labs (NTBL) expects to begin its Phase 2 volasertib AML program in the coming months following the SOHO 2024 presentation.

What is the title of Notable Labs' poster presentation at SOHO 2024?

The poster presentation is titled 'Revival of the polo-like kinase 1 (PLK1) inhibitor volasertib in relapsed/refractory acute myeloid leukemia'.

What is Notable Labs' (NTBL) Predictive Medicine Platform used for?

Notable Labs' (NTBL) Predictive Medicine Platform (PMP) is used to identify and develop new cancer therapies, supporting the company's precision oncology approach.